Oxathiazinane derivatives display both antineoplastic and antibacterial activity: a structure activity study,Journal of Cancer Research and Clinical Oncology

当前位置： X-MOL 学术 › J. Cancer Res. Clin. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Oxathiazinane derivatives display both antineoplastic and antibacterial activity: a structure activity study
Journal of Cancer Research and Clinical Oncology ( IF 2.7 ) Pub Date : 2023-05-12 , DOI: 10.1007/s00432-023-04799-8
B Majchrzak-Stiller ₁ , M Buchholz ₁ , I Peters ₁ , J Strotmann ₁ , J Möhrke ₁ , L Zelichowski ₁ , L Oehlke ₁ , C Quensel ₁ , D Fein ₁ , P Höhn ₁ , T Müller ₂ , W Uhl ₁ , C Braumann _{1,

3}

Affiliation

Purpose

The Oxathiazinane substance class is characterized by a high diversity of chemical structures yet to be fully investigated. Our research group recently proved that the 1.4.5-oxathiazine-4.4-dioxide, known as substance GP-2250, possesses antineoplastic properties as shown on pancreatic carcinoma. This current study aims to gain insights into the structure and activity relationship of a series of different Oxathiazinanes regarding their antineoplastic activity and the potential correlation with antibacterial activity. We investigated the newly synthesized Oxathiazinane derivatives: 2255, 2256, 2287, 2289, 2293 and 2296 in comparison to GP-2250.

Methods

The antineoplastic effect was evaluated in different cancer entities (breast, skin, pancreas and colon cancer cell lines) by viability, proliferation, and cell migration assays in vitro. Disc diffusion tests were performed on various bacteria strains to examine the antibacterial potential. Additionally, reactive oxygen species (ROS) assays were conducted to investigate mechanistic aspects.

Results

The substances GP-2250, 2293, 2289 and 2296 not only showed antineoplastic activity in four different cancer entities but also antibacterial effects, as tested on multiple bacteria strains including MRSA (Methicillin-resistant Staphylococcus aureus). Furthermore, these substances also induced high ROS levels up to 110% in the treated cancer cell lines compared to untreated control cells. These results indicate a correlation between an antineoplastic capacity and antibacterial properties of these derivatives. Both activities appear to be ROS driven. The Oxathiazinane derivatives 2255, 2256 and 2287 lacked both, antineoplastic and antibacterial activity.

Conclusion

Thus, a comparable structure activity relationship became apparent for both the antineoplastic and antibacterial activity.

中文翻译：

噁噻嗪烷衍生物同时具有抗肿瘤和抗菌活性：结构活性研究

目的

Oxathiazinane 物质类别的特点是化学结构高度多样化，尚未得到充分研究。我们的研究小组最近证明，1.4.5-噁噻嗪-4.4-二氧化物，称为物质 GP-2250，具有抗肿瘤特性，如胰腺癌所示。目前的这项研究旨在深入了解一系列不同 Oxathiazinanes 的结构和活性关系，关于它们的抗肿瘤活性以及与抗菌活性的潜在相关性。我们研究了新合成的 Oxathiazinane 衍生物：2255、2256、2287、2289、2293 和 2296 与 GP-2250 的比较。

方法

通过体外活力、增殖和细胞迁移测定评估不同癌症实体（乳腺癌、皮肤癌、胰腺癌和结肠癌细胞系）的抗肿瘤作用。对各种细菌菌株进行圆盘扩散试验，以检查抗菌潜力。此外，还进行了活性氧（ROS）测定以研究机制方面。

结果

物质 GP-2250、2293、2289 和 2296 不仅在四种不同的癌症实体中显示出抗肿瘤活性，而且在包括 MRSA（耐甲氧西林金黄色葡萄球菌）在内的多种细菌菌株上测试时也显示出抗菌作用。此外，与未处理的对照细胞相比，这些物质还在处理过的癌细胞系中诱导了高达 110% 的高 ROS 水平。这些结果表明这些衍生物的抗肿瘤能力和抗菌特性之间存在相关性。这两个活动似乎都是由 ROS 驱动的。Oxathiazinane 衍生物 2255、2256 和 2287 同时缺乏抗肿瘤和抗菌活性。